PETX Aratana Therapeutics Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Aratana Therapeutics, Inc. -- PETX

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Aratana Therapeutics, Inc. (NASDAQ:PETX) concerning possible violations of federal securities laws.

On February 6, 2017, Aratana revealed that the Center for Veterinary Medicine ("CVM") had requested more information about ENTYCE, its appetite stimulation drug. Aratana informed shareholders that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's request was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.” Following this news, Aratana stock has fallen as much as $1.57 per share, or 19.55%, to a low of $6.46 during intraday trading on February 6, 2017. To obtain additional information, go to:

http://zlk.9nl.com/aratana-therapeutics-petx

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Eduard Korsinsky, Esq.

30 Broad Street - 24th Floor

New York, NY 10004

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

EN
06/02/2017

Underlying

PETXAratana Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aratana Therapeutics Inc

GlobalData Department
  • GlobalData Department
EUR 227.65
PETX Aratana Therape...

Aratana Therapeutics Inc (PETX) - Pharmaceuticals & Healthcare - Deals...

Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim for the treatment serious conditions in pets. Aratana offers products candidates, which include Galliprant (AT-001), for the treatment of osteoarthritis pain and inflammation; Entyce (AT-002), for a...

PETX ARATANA THERAPEUTICS INC
10/23/18 October 23, 2018 19 EN
Free Trial
PETX Aratana Therape...

1 director sold

A director at Aratana Therapeutics Inc sold 75,000 shares at 6.057USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

PETX ARATANA THERAPEUTICS INC
09/21/18 September 21, 2018 1 EN
 PRESS RELEASE
Free
PETX Aratana Therape...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc. (NASDAQ: PETX) between March 16, 2015 and February 3, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Dezi v. Aratana Therapeutics, Inc., et al. (Case No. 1:17-cv-01446) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/arat...

March 22, 2017 1 EN
 PRESS RELEASE
Free
PETX Aratana Therape...

PETX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ: PETX) securities between March 16, 2015 and February 3, 2017. Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made false and/or misleading...

March 17, 2017 1 EN
 PRESS RELEASE
Free
PETX Aratana Therape...

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadli...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Aratana Therapeutics, Inc. (Nasdaq:PETX) (“Aratana” or the “Company”) securities during the period between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 7, 2017...

March 14, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch